The Global Leuprolide Acetate Market is expected to grow at an approximate CAGR of 5.4% during the forecast period.
Leuprolide is a synthetic nonapeptide acetate salt and is analogous to the gonadotropin-releasing hormone. The salt shows a therapeutic effect by binding to the receptors of the gonadotropin-releasing hormone. Leuprolide acetate is widely used as a therapeutic agent for the treatment of prostate cancer in men and precocious and uterine fibroids in women. Upset stomach, breast swelling, vaginal bleeding, impotence, and others are some of the major side effects associated with the use of this salt.
The increasing prevalence of prostate cancer and the uterine fibroid is expected to be a major driver for the market growth during the forecast period. In 2015, according to the World Cancer Research Fund International, approximately 1.1 million cases of prostate cancer were recorded in 2014, accounting for ~8% of all the new cancer cases. Moreover, according to a study published in the BMC Women’s Health Journal in 2012, the self-reported prevalence of uterine fibroids was estimated to range from 4.5% in the U.K to 9.8% in Italy.
Get a Sample Copy of This Report @ https://www.marketresearchfuture.com/sample_request/785 .
Additionally, the increasing geriatric population and growing pharmaceutical and healthcare sectors boost the market growth. According to the Population Reference Bureau in 2016, the Americas geriatric population is estimated to be more than double and reach about 98 million by 2060. However, factors such as low per capita healthcare expenditure, stringent government policies, and the presence of alternative treatments in the market are likely to restrain the market growth during the forecast period.
The key players in the global leuprolide acetate market are TOLMAR Pharmaceuticals, Inc. (U.S.)
Varian Pharmed (Iran), avenit AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Ltd. (India), Livzon Pharmaceutical Group Co., Ltd. (China), Beijing Biote Pharmaceutical Co., Ltd (China), Soho-YImIng (China), AbbVie Inc. (U.S.), Sanofi (France), Astellas Pharma (Japan), Abbott (U.S), Merck KGaA (Germany), Pfizer Inc. (U.S.), and others.
The Americas holds the largest segment of the global leuprolide acetate market. The increasing prevalence of prostate cancer and uterine fibroids, the presence of a well-developed healthcare sector, and growing healthcare expenditures are expected to be the major drivers for the market growth during the forecast period. Additionally, the presence of key players such as TOLMAR Pharmaceuticals, Inc., AbbVie Inc., Abbott, Pfizer Inc., and others are expected to boost the market growth during the forecast period.
Get Attractive Discount on This Report @ https://www.marketresearchfuture.com/check-discount/785 .
Europe is second in the global leuprolide acetate market. This can be attributed to the increasing patient population, rising availability of funds for research and development, and the presence of developed economies such as the U.K., Italy, France, and others within the region. According to the Cancer Research U.K., approximately 47,151 new cases of prostate cancer were reported in 2015, accounting for 11,287 deaths within the same year.
1 Report Prologue
2 Market Introduction
2.2 Scope of the Study
2.2.1 Research Objective
3 Research Methodology
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
4 Market Dynamic
Inquire about This Report @ https://www.marketresearchfuture.com/enquiry/785 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Akash Anand
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –